{"id":242183,"date":"2026-03-19T12:34:02","date_gmt":"2026-03-19T11:34:02","guid":{"rendered":"https:\/\/cannaspeaks.com\/?p=242183"},"modified":"2026-03-19T12:32:36","modified_gmt":"2026-03-19T11:32:36","slug":"cbd-compliance-spain-uk","status":"publish","type":"post","link":"https:\/\/cannaspeaks.com\/es\/cbd-compliance-spain-uk\/","title":{"rendered":"CBD Compliance in Spain vs. the UK: What Every Cannabis Brand Needs to Know in 2026"},"content":{"rendered":"
A British CBD brand decides to expand into Spain. They have their ingestible product ready, their packaging sorted, their website translated. They launch.<\/p>\n
Within weeks, the product gets pulled.<\/p>\n
What happened? In Spain, ingestible CBD products aren’t authorised. That’s it. It didn’t matter that they’d been on the UK market for two years with a live FSA application. The frameworks are different, the rules are different, and what you’re allowed to write on a label is different too.<\/p>\n
This isn’t a rare story. Companies moving between Spain and the UK routinely assume the regulatory logic of one market transfers cleanly to the other. It doesn’t.<\/p>\n
The two countries shared a common foundation until Brexit. Since then they’ve been pulling apart in ways that have real operational consequences \u2014 for product formulation, for labelling, and especially for the texts that describe what a product is and does.<\/p>\n
What follows covers the three compliance gaps that cause the most trouble for brands navigating both markets, with specific data on what’s changed and what it actually means for your product copy and marketing claims.<\/p>\n
This article is for informational purposes only and does not constitute legal advice. Regulations in this sector change frequently \u2014 always consult a qualified legal professional before entering a new market.<\/em><\/p>\n\n
Same plant, different rulebook: how Spain and the UK diverged on CBD<\/h2>\n\n \n<\/figure>\n
Until 2020, both countries operated under the same EU Novel Food Regulation, which in 2018 classified CBD extracts as novel foods requiring authorisation before sale for human consumption. Then Brexit happened, and the UK’s Food Standards Agency built its own parallel pathway.<\/p>\n
Today you have two separate regulatory processes with different safety thresholds, different timelines, and increasingly different standards for what data an application needs to include. Both are slow.<\/p>\n
As of early 2026, no ingestible CBD product has received full authorisation in either market<\/strong>. The UK is further along \u2014 three CBD isolate applications have received positive safety assessments from the FSA, which is a meaningful step, though not the same as market authorisation. In the EU, including Spain, EFSA has not authorised any ingestible CBD product, and its September 2025 update raised the bar for applications significantly.<\/p>\n
So when a brand says “we’re compliant in one market, we just need to localise for the other” \u2014 that’s the assumption that gets them into trouble.<\/p>\n
\n
Three compliance gaps that trip up brands expanding between Spain and the UK<\/h2>\n
1. What you can actually sell<\/h3>\n
This is where the difference is starkest, and where brands get the most expensive surprises.<\/p>\n
In Spain, ingestible CBD products \u2014 oils marketed as dietary supplements, gummies sold for consumption \u2014 sit in a legal grey zone that is, in practice, a prohibition. The AEMPS<\/strong> has not registered CBD as a food supplement.<\/p>\n
Products for external use and cosmetics can be sold legally under EU cosmetic safety regulations. The 0.2% THC<\/strong> figure the industry commonly cites applies to hemp cultivation, not to finished cosmetic products \u2014 but it functions as a practical reference point for formulators. Flowers exist as aromatic or collectible products.<\/p>\n
An ingestible oil marketed as a supplement? Routinely confiscated. For any brand looking to sell CBD legally in Spain, the only clear-cut path right now is cosmetics and topicals.<\/strong><\/p>\n
In the UK it’s different, though not simple. Ingestible products can remain on the market if they’re linked to a credible, active application on the FSA’s public list. Products without that link are considered unauthorised and should be removed from sale. The FSA has been clear about this.<\/p>\n
\n
A product your UK team has been selling legally for two years could be a seized item on day one in Spain. Category comes before language.<\/p>\n<\/blockquote>\n
2. THC limits \u2014 not what most people think<\/h3>\n
There’s a misconception here that causes genuine problems, and it’s worth being direct about it.<\/p>\n
The 0.2% THC<\/strong> figure that circulates everywhere refers to the THC limit for hemp cultivation in the EU. It is a cultivation standard. It is not a finished product safety threshold, and treating it as one leads brands into formulation and labelling decisions they’ll later have to undo.<\/p>\n
For finished CBD products in the UK, the FSA established in 2025 a safe upper daily intake of 0.07mg of THC<\/strong> \u2014 corresponding to a provisional acceptable daily intake of 10mg of CBD per day<\/strong> for healthy adults.<\/p>\n
That 10mg figure replaced the earlier 70mg guidance in 2023, after the FSA reviewed safety data submitted by industry during the novel food process. It’s advisory rather than a hard legal cap, but applications that have cleared positive safety assessments adhere to it, and the FSA is encouraging existing brands to reformulate.<\/p>\n
In Spain, there’s no officially published finished-product THC threshold for ingestibles \u2014 because those products aren’t officially recognised in the first place. For cosmetics, EU cosmetic safety regulations apply their own criteria, separate from the cultivation standard.<\/p>\n
CBD labelling requirements in the UK now need to reflect both the 10mg ADI and safety warnings for vulnerable groups<\/strong> \u2014 something many brands formatted before the 2023 revision haven’t adjusted yet.<\/p>\n
3. What you can say \u2014 where most brands underestimate the risk<\/h3>\n\n \n<\/figure>\n
This is the gap that gets the least attention and causes the most visible problems. You can have the right product, the right formulation, the right THC levels \u2014 and still end up with a compliance issue because of your copy.<\/p>\n
In both markets, medical claims without regulatory approval are prohibited. But the specific language risks differ, and some of them are surprisingly granular.<\/p>\n
In the UK, the word “dose”<\/strong> on a food product can trigger reclassification as a medicine under MHRA criteria. Not the intent \u2014 the word itself, because it implies therapeutic administration. Similarly, phrases like “clinically proven,” “treats,” or “relieves” push a product toward medicine territory. The ASA<\/strong> actively investigates CBD advertising for exactly these signals, and the consequences of getting it wrong aren’t just a slap on the wrist.<\/p>\n
In Spain, the AEMPS<\/strong> prohibits marketing CBD as a treatment or promoting it for any therapeutic use, regardless of how a brand interprets the available scientific literature. Claims like “reduces anxiety” or “improves sleep quality” aren’t permitted in Spanish product texts or marketing materials \u2014 and to be clear, they’re equally problematic under UK advertising standards.<\/p>\n
\n
A text written for the UK market, translated word for word into Spanish, doesn’t just have linguistic issues. It may make claims that are prohibited under a completely different regulatory framework.<\/p>\n
That’s not a translation problem. It’s a localisation problem \u2014 and the two are not the same thing.<\/p>\n<\/blockquote>\n
\n
What actually happens when brands get this wrong<\/h2>\n
The costs range from operational disruption to something harder to quantify.<\/p>\n
In Spain, enforcement against grey-market CBD operators has been consistent in recent years \u2014 products confiscated and stores raided even in markets where tolerance was historically higher. In the UK, the FSA’s 2025 guidance update on THC limits and the revised CBD daily intake has prompted a round of reformulations. Packaging that was compliant twelve months ago may need to change now.<\/p>\n
But the less obvious cost is reputational. A product recall leaves a digital trace. Distributors remember. Retailers who got caught stocking something non-compliant don’t forget.<\/p>\n
For a brand in the early stages of building presence in a new market, a compliance failure in year one can quietly close doors that take a long time to reopen.<\/p>\n
Most of this is preventable. The root cause is almost always the same: assuming that what works in the home market works elsewhere, and translating materials without auditing the claims first.<\/p>\n
\n
A practical starting point \u2014 before you translate anything<\/h2>\n
Three things worth having in place before any product text leaves your desk for a new market.<\/p>\n
Know the product’s regulatory category in the destination market first.<\/strong> Is it a cosmetic? A food supplement? An aromatic product? The category determines which agency regulates it, what claims are permitted, and what labelling is mandatory. This step comes before translation, not after.<\/p>\n
Audit your existing texts for language that doesn’t travel.<\/strong> Identify the terms that create regulatory risk in the destination market \u2014 words that imply medicinal use, dosage language, efficacy claims. This doesn’t require a lawyer. It requires knowing which words activate which categories, and doing that work before you translate rather than after you launch.<\/p>\n
Build separate review processes for each market.<\/strong> Spain and the UK have different regulatory bodies, different enforcement patterns, and different standards for what belongs on a label. A single compliance workflow that just changes the language doesn’t account for that. Each market needs its own validation step.<\/p>\n\n
The compliance gap is also a language gap<\/h2>\n
The more you work through these differences, the clearer it becomes that compliance in this sector isn’t just a legal problem. It’s a language problem.<\/p>\n
The same product, described in the same way, can be compliant in one jurisdiction and not in another. The regulatory frameworks don’t just differ in what products are allowed \u2014 they differ in what language is allowed to describe them.<\/strong><\/p>\n
That’s not something a generic translation resolves. It requires understanding both the regulatory context and the specific linguistic register of each market: what a word implies, what category it invokes, what a regulator reads when they see it on a label.<\/p>\n
![\"Hemp](\"https:\/\/cannaspeaks.com\/wp-content\/uploads\/2026\/03\/Spain-vs-UK2.jpg\")
![\"CBD](\"https:\/\/cannaspeaks.com\/wp-content\/uploads\/2026\/03\/Spain-vs-UK3.jpg\")